Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Patient involvement in health policy is a patchwork across the EU. Putting the lived experience front and centre of policy-making was prioritised at a recent high-level policy event organised by the ...

with submissions to the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency ...

Highlights: Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis ; Orphan D ...

Global health is likely to be radically altered with Donald Trump in the White House. For starters, the president-elect has ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...